SCHEMBL3961632

SCHEMBL3961632

Cc1cc(Nc2cc3cc(Br)ccc3c(Cl)n2)n[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.43
PAK4 O96013 4/20 0.42
PLK4 O00444 3/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
CCNA1 P78396 1/20 0.42
GSK3B P49841 4/20 0.42
PIK3C3 Q8NEB9 3/20 0.42
AURKA O14965 6/20 0.41
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
ITK Q08881 1/20 0.40
IGF1R P08069 2/20 0.39
AURKB Q96GD4 2/20 0.39
SRC P12931 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975930 0.90 PAK4 (0.42) NTRK1PAK4PLK4CCNA2CDK2
SCHEMBL3972285 0.84 CCNA2 (0.45) NTRK1PAK4PLK4CCNA2CDK2
SCHEMBL14520028 0.84 PAK4 (0.42) NTRK1PAK4PLK4GSK3BPIK3C3
SCHEMBL3966868 0.82 AURKA (0.50) NTRK1PAK4GSK3BAURKANPC1
SCHEMBL3967592 0.82 AURKA (0.51) PAK4PLK4GSK3BPIK3C3AURKA
SCHEMBL3971009 0.79 NTRK1 (0.40) NTRK1PAK4PLK4CCNA2CDK2
SCHEMBL3971328 0.78 AURKA (0.40) PAK4PLK4GSK3BPIK3C3AURKA
SCHEMBL3967146 0.76 AURKA (0.43) PAK4PLK4GSK3BPIK3C3AURKA
SCHEMBL3974480 0.76 CCNA2 (0.45) NTRK1PAK4PLK4CCNA2CDK2
SCHEMBL14520024 0.76 PAK4 (0.42) NTRK1PAK4PLK4GSK3BPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 NTRK1 4316/4885PAK4 1324/4885PLK4 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.